机构:[1]Gracell Biotechnol Co Ltd, Shanghai, Peoples R China[2]920th Hosp Joint Logist Support Force Peoples Lib, Kunming, Yunnan, Peoples R China[3]Army Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China[4]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China昆明医科大学附属第一医院[5]Gracell Biotechnol Shanghai Co Ltd, Shanghai, Peoples R China
第一作者机构:[1]Gracell Biotechnol Co Ltd, Shanghai, Peoples R China[2]920th Hosp Joint Logist Support Force Peoples Lib, Kunming, Yunnan, Peoples R China[3]Army Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China[4]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China[5]Gracell Biotechnol Shanghai Co Ltd, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Wang Xinxin,Li Shiqi,Gao Lei,et al.Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).[J].JOURNAL OF CLINICAL ONCOLOGY.2020,38(15):
APA:
Wang, Xinxin,Li, Shiqi,Gao, Lei,Yuan, Zhongtao,Wu, Kun...&Zhang, Xi.(2020).Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)..JOURNAL OF CLINICAL ONCOLOGY,38,(15)
MLA:
Wang, Xinxin,et al."Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).".JOURNAL OF CLINICAL ONCOLOGY 38..15(2020)